Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dual Integrin Antagonist · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Dual Integrin Antagonist | DRUG | - |
Inclusion Criteria: * Persistent asthma for more than one year * Current treatment for asthma with short acting inhaled beta 2 agonists (such as albuterol) only * In good health ad demonstrated by medical history and physical exam * Negative urine pregnancy test * Commitment to use two forms of eff...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Dual Integrin Antagonist is an investigational small molecule being developed by Roche Holding AG (RHHBY) for the treatment of asthma. It has been evaluated in Phase 2 clinical trials in asthmatic patients, including those not treated with inhaled corticosteroids and those with moderate persistent asthma.
Dual Integrin Antagonist is a small molecule that targets integrins, which are cell surface receptors involved in cell adhesion and signaling. By inhibiting integrin activity, the drug aims to modulate inflammatory responses relevant to asthma. The specific integrin subtypes targeted are not disclosed in the available clinical trial information.
Dual Integrin Antagonist is being developed by Roche Holding AG, a multinational healthcare company traded under the ticker RHHBY. The drug is currently in clinical development for asthma, with Phase 2 trials completed.
Dual Integrin Antagonist is in Phase 2 clinical development for asthma. Two Phase 2 trials have been completed, but the drug is not yet approved and remains investigational. No active trials are currently listed for this asset.
Dual Integrin Antagonist has been studied in two completed Phase 2 trials: NCT00048009, which evaluated various doses in asthmatic patients not treated with inhaled corticosteroids, and NCT00048022, which assessed efficacy and safety in moderate persistent asthma. Both trials enrolled adults aged 18 years and older.